4.6 Article

Risk Implications of the New CKD Epidemiology Collaboration (CKD-EPI) Equation Compared With the MDRD Study Equation for Estimated GFR: The Atherosclerosis Risk in Communities (ARIC) Study

期刊

AMERICAN JOURNAL OF KIDNEY DISEASES
卷 55, 期 4, 页码 648-659

出版社

W B SAUNDERS CO-ELSEVIER INC
DOI: 10.1053/j.ajkd.2009.12.016

关键词

Estimated glomerular filtration rate; cardiovascular disease; end-stage renal disease; epidemiology

资金

  1. National Institutes of Health (NIH) National Heart, Lung, and Blood Institute (NHLBI) [N01-HC-55015, N01-HC-55016, N01-HC-55018, N01-HC-55019, N01-HC-55020, N01-HC-55021, N01-HC-55022, T32HL07024]
  2. Japan Society for the Promotion of Science
  3. NIH National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) [K01DK076595, R01DK076770]
  4. National Kidney Foundation

向作者/读者索取更多资源

Background: The Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) recently published an equation for estimated glomerular filtration rate (eGFR) using the same variables (serum creatinine level, age, sex, and race) as the Modification of Diet in Renal Disease (MDRD) Study equation. Although the CKD-EPI equation estimates GFR more precisely compared with the MDRD Study equation, whether this equation improves risk prediction is unknown. Study Design: Prospective cohort study, the Atherosclerosis Risk in Communities (ARIC) Study. Setting & Participants: 13,905 middle-aged participants without a history of cardiovascular disease with median follow-up of 16.9 years. Predictor: eGFR. Outcomes & Measurements: We compared the association of eGFR in categories (>= 120, 90-119, 60-89, 30-59, and <30 mL/min/1.73 m(2)) using the CKD-EPI and MDRD Study equations with risk of incident end-stage renal disease, all-cause mortality, coronary heart disease, and stroke. Results: The median value for eGFR(CKD-EPI) was higher than that for eGFR(MDRD) (97.6 vs 88.8 mL/min/1.73 m(2); P < 0.001). The CKD-EPI equation reclassified 44.9% (n = 3,079) and 43.5% (n = 151) of participants with eGFR(MDRD) of 60-89 and 30-59 mi./min/1.73 m(2), respectively, upward to a higher eGFR category, but reclassified no one with eGFR(MDRD) of 90-119 or <30 mL/min/1.73 m(2), decreasing the prevalence of CKD stages 3-5 from 2.7% to 1.6%. Participants with eGFR(MDRD) of 30-59 mL/min/1.73 m(2) who were reclassified upward had lower risk compared with those who were not reclassified (end-stage renal disease incidence rate ratio, 0.10 [95% CI, 0.03-0.33]; all-cause mortality, 0.30 [95% CI, 0.19-0.48]; coronary heart disease, 0.36 [95% CI, 0.21-0.61]; and stroke, 0.50 [95% CI, 0.24-1.02]). Similar results were observed for participants with eGFR(MDRD) of 60-89 mL/min/1.73 m(2). More frequent reclassification of younger, female, and white participants explained some of these trends. Net reclassification improvement in participants with eGFR < 120 mL/min/1.73 m(2) was positive for all outcomes (P < 0.001). Limitations: Limited number of cases with eGFR < 60 mUmin/1.73 m(2) and no measurement of albuminuria. Conclusions: The CKD-EPI equation more appropriately categorized individuals with respect to long-term clinical risk compared with the MDRD Study equation, suggesting improved clinical usefulness in this middle-aged population. Am J Kidney Dis 55:648-659. (C) 2010 by the National Kidney Foundation, Inc.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.6
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据